Yes, a I great that's think question.
I not the speak against product speak will of think product sort about bring the me rather attributes So speak our -- to another to that than and we let marketplace.
disposable we'll palm-sized obviously, should not So potentially bring nebulizers of portable, we simple treprostinil allow burden the patients a And introduction device, replace therapy inhaled but which portability. of need. should for with the earlier to make in only
that the I that thing we seen think therapy. tolerated a a have we've -- highly well-tolerated is
is But has the what can associated vis-à-vis dose with good. seconds, beyond the Tyvaso escalate and obviously. Tyvaso, YUTREPIA, we It toxicities allowed. unique avoids is about what's parenteral both systemic tolerability So significantly process oral that
print. through inhaled with our So therapeutic dry powder we'll change treprostinil formulation the of index
in Importantly, There's from to no an tolerability no label excipient. warning. black safety, of addition sort risk our has box
that's an the distinguish could product. think that I important lever So
studies, of have an actually As abstract in dose target times week. I which gone readily, long-term And three said, we've can just few label Tyvaso open do easily breasts. our at in this we'll a next ATS it's administered to the titratable we
parenteral. in move the but paradigm next We So therapies, likely you're as of use. along ease for and can would terms Again, them treatment the change other keep a seeing good we longer reported I very before to in seeing think therapy real be we're halo they durability. most ATS, patients treprostinil
you're think different curve. a report curve, I retention going obviously aspect have to which important an that's a So because different revenue
In at room terms can our its of temperature product storage, lifetime. for we store product
important devices, low resistant is inhale dose. it's to So and One And that's important. the low resistance to deliver becomes critically regard And even device, two we a thing now where that's is in very so this -- use easy the things. position more requirement road in I'll the to restrictive in finally, for compromised important perhaps they're no down obstructive of pulmonary what dependents. is a hypertension. where device, to three or addition disease patients the lung And there's [indiscernible] the with call from really, then one regards
drop in and the can product the you will drug, drug can number lift encapsulated, spillage. is because ways do no You the device any there's and hold device the of it
in other use. it's like simple, this and and used their to CF So clinical companies patients easy very already device, using Gossamer COPD -- It's own in [Inlet] in commercially. There's trials.
So total, is What and it's true. tried patients, will we transition very rapid go that a comparative And to YUTREPIA. to very to we Tyvaso mean, go to this therapy inhaled expect a therapy a and to I'd call think, what preferentially, in good on all to that. DPI. both from And there's new
time, XXXX And Tyvaso Ventavis second that new we market with launched in when was Tyvaso in transitioned it back the look particularly marketplace. to launched, starts. you in market, patient to rapidly over If already
we're without YUTREPIA. of seeing that play this that therapeutic -- improvement So convenience a and index sort with pharmacologic was just
are So what we lower again, other that estimates than would I've predict. seen
we that the transition And longer see think Tyvaso from the a is for earlier as patient YUTREPIA. X,XXX opportunity new so of with steady retention, I to XX% state. playing out would of it we or itself we massive. in to market day which quite think adds And the XX% the that's then is of market to will X,XXX kind and approximately YUTREPIA, use grow how that the then would capture -- probably base obviously essence the estimate which and the presents
